Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 17
4 116
3 132
2 41
1 23
NEB 3
Curative setting
327
A 43
C 3
NEB 1
ESMO-MCBS Scores by tumour type
Non-curative setting
Breast Cancer 38
Central Nervous System Malignancies 0
Endocrine Tumours 20
Gastrointestinal Cancers 62
Genitourinary Cancers 60
Gynaecological Malignancies 34
Head and neck cancer 12
Melanoma 3
Refractory NTRK fusion-positive cancers 2
Sarcoma 9
Skin Cancers 24
TMB-H solid tumours 1
Thoracic Malignancies 66
dMMR/MSI-H solid tumour 1
Curative setting
Breast Cancer 8
Central Nervous System Malignancies 1
Endocrine Tumours 0
Gastrointestinal Cancers 14
Genitourinary Cancers 4
Gynaecological Malignancies 0
Head and neck cancer 1
Melanoma 3
Refractory NTRK fusion-positive cancers 0
Sarcoma 2
Skin Cancers 9
TMB-H solid tumours 0
Thoracic Malignancies 4
dMMR/MSI-H solid tumour 0

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on To evaluate ESM0-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Nivolumab - Placebo Adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection CheckMate 274 Genitourinary Cancers Urothelial Carcinoma - CheckMate 274

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    Nivolumab Fluoropyrimidine and platinum-based combination ChT ChT First-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥1% CheckMate 648 Gastrointestinal Cancers Oesophageal Cancer PD-L1 expression ≥1% CheckMate 648

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Pembrolizumab - Single arm Adult and pediatric patients with recurrent, locally advanced or metastatic Merkel cell carcinoma KEYNOTE-017 Skin Cancers Merkel cell carcinoma - KEYNOTE-017

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Pembrolizumab - Ipilimumab Treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma KEYNOTE-006 Melanoma Cutaneous Melanoma - KEYNOTE-006

    A

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a/F1
      4

      A
    Sorafenib - Placebo Treatment of HCC SHARP Gastrointestinal Cancers Hepatobiliary Cancers - Hepatocellular Carcinoma - SHARP

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      3
    177Lu-PSMA-617 Best standard of care (restricted) Best standard of care (restricted) In combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy. VISION Genitourinary Cancers Prostate cancer PSMA-positive mCRPC VISION

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Relatlimab Nivolumab Nivolumab Treatment of adult and paediatric patients 12 years of age or older with unresectable or metastatic melanoma RELATIVITY-047 Melanoma Cutaneous Melanoma - RELATIVITY-047

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      3
    Olaparib - Placebo Adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant ChT OlympiA Breast Cancer Early Breast Cancer gBRCAm HER2-negative OlympiA

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    Pembrolizumab - Single arm Unresectable or metastatic MSI-H or dMMR CRC after previous fluoropyrimidine-based combination therapy KEYNOTE-164 Gastrointestinal Cancers Colorectal Cancer dMMR or MSI-H KEYNOTE-164

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Pembrolizumab - Single arm cohort study (Phase II) Treatment of MSI-H or dMMR tumours in adults with unresectable or metastatic gastric cancer, who have disease progression on or following at least one prior therapy. KEYNOTE-158 Gastrointestinal Cancers Gastric Cancer dMMR or MSI-H KEYNOTE-158

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Pembrolizumab - Single arm cohort study (Phase II) Treatment of MSI-H or dMMR tumours in adults with unresectable or metastatic small intestine cancer, who have disease progression on or following at least one prior therapy. KEYNOTE-158 Gastrointestinal Cancers Small intestine dMMR or MSI-H KEYNOTE-158

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Pembrolizumab - Single arm cohort study (Phase II) Treatment of MSI-H or dMMR tumours in adults with unresectable or metastatic biliary cancer, who have disease progression on or following at least one prior therapy. KEYNOTE-158 Gastrointestinal Cancers Biliary tract cancer dMMR or MSI-H KEYNOTE-158

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Pembrolizumab Lenvatinib Treatment of physician's choice (doxorubicin or paclitaxel) Patients with advanced or recurrent endometrial carcinoma who have progressed following prior platinum-containing therapy in any setting and who are not candidates for curative surgery or RT KEYNOTE-775 Gynaecological Malignancies Endometrial Cancer - KEYNOTE-775

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Pembrolizumab Lenvatinib Treatment of physician's choice (doxorubicin or paclitaxel) Patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for curative surgery or RT KEYNOTE-775 Gynaecological Malignancies Endometrial Cancer - KEYNOTE-775

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.